Nutrigenomics Testing Market
Nutrigenomics Testing Market is segmented By Product Type (Reagents and Kits, Services), By Application (Obesity, Diabetes, Cancer, Cardiovascular Disease, Others), By End-User (Hospitals, Clinics, Diagnostic Centers, Ambulatory Surgery Center, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.
Nutrigenomics Testing Market is estimated to reach at a CAGR of 13.5% during the forecast period (2022-2029).
Nutrigenomics is the study of how diet and nutrition affect the expression of a person's genetic makeup and dietary variables that protect the genome from damage. While nutrigenomic testing accurately recognizes every individual's genetic protein variations involved in enzyme conversion, nutritional delivery, and signalling pathways in the cell to identify metabolic shortcomings.
Nutrigenomics Testing Market
|
Metrics |
Details |
|
Market CAGR |
13.5% |
|
Segments Covered |
By Product Type, By Application, By End-User, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
Market Dynamics:
Companies offering genetic and nutrigenetic information to the public are driving market growth.
Specialized companies offer the public access to genetic and nutrigenetic information, via direct-to-consumer genetic testing (DTC-GT), without the need for intermediary health professionals. DTC-GT is promoted as a new tool for consumers who wish to investigate their genetic susceptibility and those searching for tailored nutritional recommendations. These tests are available for purchase online and are designed for use at home. The company usually supplies a sample collection kit selling the test (saliva or cheek swab). After that, the sample is mailed to be analyzed. Finally, the results are mailed or emailed to the customer. DTC-GT providers frequently market and offer individualized meal plans, dietary supplements, or fitness regimens to provide information on the risk of monogenic illnesses like lactose intolerance (LI). Therefore, specialized companies offering genetic and nutrigenetic information to the public online and for home use has led to the increasing demand for nutrigenomics testing, which is expected to drive the growth of the market.
Rapid advancement in omic technologies for the diagnosis of lactose intolerance is expected to drive market growth.
Omic technologies such as proteomics, genomics, and metabolomics combine with advanced bioinformatics to be broadly used for identifying diseases based on protein pathways. Personalized nutrition (PN) has opened up due to recent discoveries in the "omics" sector and a growing focus on preventive health. PN is now a major theme in organizations' strategic plans involved in healthcare, food, and nutrition research. For instance, lactose intolerance is a condition resulting from inadequate production of the enzyme lactase in the small intestine due to genetic variation in the lactase gene. The diagnosis and treatment of lactose intolerance (LI), a prevalent illness with a strong inter-individual component, is investigated as an interesting illustration of these technologies' potential function. Nutrigenetics is a branch of genetics that studies polymorphism frequency in a population and offers data on each genotype's metabolic reaction to nutrition. Healthcare professionals perform only a small percentage of genetic tests, which are critical in translating and integrating this data into individualized healthy eating recommendations for patients. The test for polymorphisms in regulatory sequences of the LCT gene is clinically available in Europe for two common polymorphisms, LCT-13910C/T and LCT-22018G/A, associated with LP in the European population. However, the use of these SNPs cannot be applied as a global diagnostic tool, given that a total of twenty-three LP variants have currently been identified in the MCM6 gene in distinct geographic regions and population groups. Therefore, the rapid advancement in omic technologies for the diagnosis of lactose intolerance has increased the demand for nutrigenomics testing, which is expected to drive the market's growth.
The lack of qualified physicians for nutrigenomics testing is expected to hamper the market growth.
There has been an exponential growth in the number of genetic testing companies in the past few years. However, only a small percentage of these tests are being sold through health care professionals (HCPs). With new emerging genetic testing companies entering the market, it is becoming more difficult for the practitioner and consumer to evaluate the credibility of the claims being made and the value of the tests being offered. HCPs appear to have minimal nutrigenomics knowledge and little confidence in choosing and understanding nutrigenetic tests. To establish an expert group of nutrigenomic practitioners, collaboration is required between educational institutions, professional organizations, and genetic testing companies. It will provide the necessary support, skills, and knowledge to ensure that the best value is extracted from nutrigenetic tests ethically and responsibly.
COVID-19 Impact Analysis:
The pandemic caused by the SARS-CoV-2 virus led to a near-worldwide lockdown and moderately showed impact on nutrigenomics testing. The market faces challenges in manufacturing and delivering testing kits due to an interrupted supply chain. Providing essential services due to lockdowns has led to reduced supply to the end-users. The pandemic is not likely to have long-term effects on end-users primary growth in the nutrigenomics testing market.
Nutrigenomics has gained awareness among the population during COVID-19. It involves testing the effects of food and other nutritional products on the genetic makeup of an individual. There has been a whirlwind past months due to the emergence of COVID-19. The medical devices firms that are manufacturing test kits are facing financial challenges as the disease brought the whole world to a full stop. The sales of a few companies experienced a downfall while others managed to stay afloat.
Segment Analysis:
By application, the obesity segment is expected to hold the largest market share in the nutrigenomics testing market.
Based on the application, the obesity segment accounted for the largest market share in 2020. The growth of this segment is benefited due to the increasing prevalence of obese people, rapid advancements in omic technologies. For instance, according to the Centers for Disease Control and Prevention, overweight and obesity are defined as abnormal or excessive fat accumulation that may impair health. It is estimated that the US obesity prevalence was 42.4% in 2017 – 2018. From 1999–2000 through 2017–2018, the US obesity prevalence increased from 30.5% to 42.4%. During the same time, the prevalence of severe obesity increased from 4.7% to 9.2%.
Moreover, the organization estimates that 3/4 of the American population will likely be overweight or obese by 2020. According to research done by the Harvard T.H. Chan School of Public Health, it is estimated that around 40% of Americans are considered obese, and 18% are considered severely obese as of 2019. Additionally, many Americans have gained significant weight since the COVID-19 crisis started, likely fueled by increased sedentary behaviour, stress and troubles such as job and income loss that make healthy eating harder. It made people more susceptible to COVID-19-related hospitalization and mortality. Likewise, the pandemic worsened many of the social and economic conditions that led to obesity. Nutrigenomics explores the interaction between genetic factors and dietary nutrient intake on various disease phenotypes such as obesity. Therefore, this novel approach might suggest a solution for the effective prevention and treatment of obesity through individual genetic profiles and help improve health conditions.
Geographical Analysis:
North America region holds the largest market share in the global nutrigenomics testing market
In 2020, North America accounted for the highest revenue share, owing to the rise in the prevalence of obesity and diabetes. In addition, technological advancements in the region have driven down costs and improved the availability and reliability of nutritional genomics testing, and increased awareness by government agencies among people are factors that are expected to boost the market in the forecast period. For instance, as per the National Diabetes Statistics Report (2020), around 34.2 million people in the United States have diabetes which counts for 10.5% of the US population. Diabetes, especially type 2 diabetes, is rising at an alarming rate in the United States. Type 2 diabetes is a lifestyle disorder most commonly due to unhealthy eating patterns, lack of exercise, and genes.
Moreover, the number of Americans diagnosed with diabetes is projected to increase 165%, from 11 million in 2000 (prevalence of 4.0%) to 29 million in 2050 (prevalence of 7.2%). Patients are extensively seeking nutrigenomic testing and advice from various sources, and web-based companies place genetic information on their portal to circulate it among patients easily. Practitioners with knowledge of nutrigenomics are also putting their information online so that customers can take advantage effortlessly and be aware of accurate information. For instance, Kline & Company, a U.S-based company, is one of the top trends in health and wellness. It is a rapidly developing field where specialists assess how individuals react to different foods and nutritional products, resulting in tailoring and recommending personalized solutions. Therefore, the increasing prevalence and raising web-based companies on giving genetic information increases the demand for nutrigenomics testing.
Competitive Landscape:
Some of the major key players in the nutrigenomics testing market are Nutrigenomix, Holistic Health, The Gene Box, Cura Integrative Medicine, Orig3n, DNA Life, Genus Health, LLC, Sanger Genomics Pvt. Ltd and Ome Ventures Inc. The major companies are adopting various strategies such as product launches, mergers, acquisitions, and collaborations to expand their share globally. For instance, in June 2020, Nutrigenomix launched a 70-gene test for personalized nutrition. The expanded panel adds to the biohacking toolkit, which will assist dietitians in making DNA-based dietary recommendations tailored to specific needs and goals.
DNALife:
Overview:
DNALife is a nutrigenomics company founded in 2013 due to a joined effort between Nordic Laboratories, a Denmark-based company that promotes individualized and preventative healthcare, and DNAlysis. The tests are operated in an ISO accredited laboratory and have the most up-to-date DNA tests specialized in general health, nutrition, and fitness. Moreover, the company offers products in Nutrigenomics, Pharmacogenomics test, Test Pairing services. It provides courses and additional educational resources for healthcare professionals to help interpret genetic tests, both online and in person.
Product Portfolio:
DNALife offers products in nutrigenomics that provide information about the interaction of genes and nutrition. Some of the products include DNA Smile, GrowBaby, DNA Health, DNA Sport, among others.
Frequently Asked Questions
What is the Projected CAGR value of the Nutrigenomics Testing Market?
Nutrigenomics Testing Market is expected to grow at a CAGR of 13.5% during the forecasting period 2022-2029.
Which region controlled the global market during 2022-2029?
North America region Controls the Nutrigenomics Testing Market during 2022-2029.
Which is the fastest growing region in the Nutrigenomics Testing Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period.